The Role of Long-Acting Bronchodilators in the Management of Stable COPD

Chest

Volumn 125, Issue 1, 2004, Pages 249-259

  Tashkin, Donald P ^a   Cooper, Christopher B ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Bronchodilators; COPD; Exacerbations; Formoterol; Global Initiative for Chronic Obstructive Lung Disease; Health status; Lung function; Salmeterol; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; FLUTICASONE; FORMOTEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PLACEBO; SALBUTAMOL; SALMETEROL; THEOPHYLLINE; TIOTROPIUM BROMIDE;

ALGORITHM; BRONCHODILATATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE EXACERBATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG USE; EAR NOSE THROAT DISEASE; EXERCISE TOLERANCE; HEALTH STATUS; HEART ARRHYTHMIA; HUMAN; HYPOXEMIA; LUNG FUNCTION; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLICATION; REVIEW; SYMPTOM; TACHYCARDIA; TREATMENT INDICATION; TREMOR; XEROSTOMIA;

EID: 1642493871     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.125.1.249     Document Type: Review

References (53)

1. Jones PW. Issues concerning health-related quality of life. Chest 1995; 107:1878-1935
2. Oostenbrink JB, Rutten-van Mölken MPMH, Koch P, et al. Costs of COPD exacerbations [abstract]. Am J Respir Crit Care Med 2001; 163:A642
3. World Health Report 2000. Health systems: improving performance. Annex table 3. Geneva, Switzerland: World Health Organization, 2000
4. Pauwels RA, Buist AS, Calverlev PMA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop Summary. Am J Respir Crit Care Med 2001; 163:1256-1276 (updated 2003; available at www.goldcopd.com. Accessed December 19, 2003)
5. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest 1999; 115:957-965
6. Boyd G, Morice AH, Pounsford JC, et al. An evaluation of salmeterol in the treatment of chronic obstructive pulmonary disease (COPD). Eur Respir J 1997; 10:815-821
7. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med 1997; 155:1283-1289
8. Gross NJE, Skorodin MS. Cholinergic bronchomotor tone in COPD: estimates of its amount in comparison with that in normal subjects. Chest 1989; 96:984-987
9. Barnes PJ. Managing chronic obstructive pulmonary disease. London, UK: Science Press, 1999; 1-80
10. Barries PJ. Bronchodilators: basic pharmacology. In: Calverley PMA, Pride, N, eds. Chronic obstructive pulmonary disease. London, UK: Chapman & Hall, 1995; 391-417
11. Lulich KM, Goldie RG, Paterson JW. β-Adrenoceptor function in asthmatic bronchial smooth muscle. Gen Pharmacol 1988; 19:307-311
12. Combivent Aerosol Study Group. In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial. Chest 1994; 105:1411-1419
13. Barnes PJ. Muscarinic receptor subtypes in airways. Life Sci 1993; 52:521-527
14. Disse B. Antimuscarinic treatment for lung diseases from research to clinical practice. Life Sci 2001; 68:2257-2564
15. Jacoby DB, Fryer AD. Interaction of viral infections with muscarinic receptors. Clin Exp Allergy 1999; 29:59-64
16. Dowling RB, Johnson M, Cole PJ, et al. Effect of salmeterol on Haemophilus influenzae infection of respiratory mucosa in vitro. Eur Respir J 1998; 11:86-90
17. Dowling RB, Johnson M, Cole PJ, et al. Effect of fluticasone propionate and salmeterol on Pseudomonas aemginosa infection of the respiratoiy mucosa in vitro. Eur Respir J 1999; 14:363-369
18. 2-adrenergic agonists in COPD. Chest 2001; 120:2-58-270
19. Casaburi R, Mahler DA, Jones PW, et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur Respir J 2002; 19:217-224
20. Vincken W, van Noord JA, Greefhorst APM, et al. Improved health outcomes in patients with COPD during 1 yr treatment with tiotropium. Eur Respir J 2002; 19:209-216
21. Donohue JF, van Noord JA, Bateman ED, et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122:47-55
22. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes in a 6-month placebo controlled trial of once-daily tiotropium compared with twice-daily salmeterol in patients with COPD. Thorax 2003; 58:399-404
23. Aalbers R, Ayres J, Backer V, et al. Formoterol in patients with chronic obstructive pulmonary disease: a randomized, controlled, 3-month trial. Eur Respir J 2002; 19:936-943
24. Dahl R, Greefhorst LAPM, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164:778-784
25. Rossi A, Kristufek P, Levine BE, et al. Comparison of the efficacy, tolerability, and safety of formoterol dry powder and oral, slow-release theophylline in the treatment of COPD. Chest 2002; 121:1058-1069
26. D'Urzo AD, De Salvo MC, Ramirez-Rivera A, et al. In patients with COPD, treatment with a combination of forinoterol and ipratropium is more effective than a combination of salbutamol and ipratropium: a 3-week, randomized, double-blind, within-patient, multicenter study. Chest 2001; 119:1347-1356
27. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic obstructive disease. Eur Respir J 2003; 21:74-81
28. 2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 163:1087-1092
29. van Noord JA, de Munck DRAJ, Bantje T, et al. Long-term treatment of chronic obstructive pulmonary disease with salmeterol and the additive effect of ipratropium. Eur Respir J 2000; 15:878-885
30. Rutten-van Mölken MPMH, Roos B, van Noord JA. An empirical comparison of the St George's Respiratory Questionnaire (SGRQ) and the Chronic Respiratory Disease Questionnaire (CRQ) in a clinical trial setting. Thorax 1999; 54:995-1003
31. Chapman KR, Arvidsson P, Chuchalin AG, et al. The addition of salmeterol 50 μg bid to anticholinergic treatment in patients with COPD: a randomized, placebo controlled trial. Can Respir J 2002; 9:178-185
32. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest 2001; 119:1661-1670
33. Cazzola M, Di Lorenzo G, Di Perna F, et al. Additive effects of salmeterol and fluticasone or theophylline in COPD. Chest 2000; 118:1576-1581
34. Mahler DA, Wire P, Horstman D, et al. Effectiveness of fluticasone propionate and salmeterol combination delivered via the diskus device in the treatment of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2002; 166: 1084-1091
35. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 2003; 361:449-456
36. Kottakis J, Cioppa GD, Creemers J, et al. Faster onset of bronchodilation with formoterol than with salmeterol in patients with stable, moderate to severe COPD: results of a randomized, double-blind clinical study. Can Respir J 2002; 9:107-115
37. Benhamou D, Cuvelier A, Muir JF, et al. Rapid onset of bronchodilation in COPD: a placebo-controlled study comparing formoterol (Foradil Aerolizer) with salbutamol (Ventodisk). Respir Med 2001; 95:817-821
38. Rennard S, Serby C, Ghafouri M, et al. Extended therapy with ipratropium is associated with improved lung function in patients with COPD: a retrospective analysis of data from seven clinical trials. Chest 1996; 110:62-70
39. Harver A, Schwartzstein RM, Killian KJ, et al. Understanding dyspnoea in COPD [abstract]: mechanisms, measurement and management. Eur Respir Rev 2002; 12:25-55
40. Mahler DA, Weinberg DH, Wells CK, et al. The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes. Chest 1984; 85:751-758
41. Witek TJ, Mahler DA. Validity and patterns of response of dyspnea measures in a 6 month bronchodilator intervention trial in COPD [abstract]. Am J Respir Crit Care Med 2002; 165:A266
42. Liesker JJ, Van De Velde V, Meysman M, et al. Effects of formoterol (Oxis Turbuhaler) and ipratropium on exercise capacity in patients with COPD. Respir Med 2002; 96:559-566
43. O'Donnell DE, Magnussen H, Aguilaniu B, et al. SPIRIVA® (tiotropium) improves exercise tolerance in COPD [abstract]. Am J Respir Crit Care Med 2002; 165:A227
44. O'Donnell DE, Magnussen H, Aguilaniu B, et al. SPIRIVA® (tiotropium) reduces exertional dyspnea in COPD [abstract]. Am J Respir Crit Care Med 2002; 165:A265
45. Jeffery PK, MacNee W, Mahler DA, et al. COPD exacerbations; causes, impacts and implications for management. Eur Respir Rev 2002; 18:1-24
46. Anthonisen NR, Manfreda J, Warren CPW, et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106:196-204
47. Rodriguez-Roisin R. Toward a consensus definition for COPD exacerbations. Chest 2000; 117:398-401
48. Burge PS, Calverley PMA, Jones PW, et al. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000; 320:1297-1303
49. Jones PW, Quirk FH, Baveystock CM, et al. A self-complete measure of health status for chronic airflow limitation: the St George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145:1321-1327
50. Guyatt GH, Berman LB, Townsend M, et al. A measure of quality of life for clinical trials in chronic lung disease. Thorax 1987; 42:773-778
51. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J 2002; 19:398-404
52. Cazzola M, Imperatore F, Salzillo A, et al. Cardiac effects of formoterol and salmeterol in patients suffering from COPD with preexisting cardiac arrhythmias and hypoxemia. Chest 1998; 114:411-415
53. 2,-agonists for chronic obstructive pulmonary disease patients with poorly reversible airflow limitation. Cochrane Database Syst Rev 2002; 3:CD001104